-
-
-
-
-
-
-
Tharimmune (THAR) Announces Positive Results of Phase 1 Trial in Healthy Subjects with TH104, its Lead Candidate for Moderate-to-Severe Pruritus in Primary Biliary Cholangitis
-
-
-
-
-
-
-
Moderna (MRNA) Reports Positive Phase 3 Data for Combination Vaccine Against Influenza and COVID-19
-
-
-
-
-
-
-
Vertex Pharma (VRTX) New Data at the European Cystic Fibrosis Conference Demonstrating Significant Benefits of Treatment with TRIKAFTA
-
-
-
-
-
-
-
Masimo Corp. (MASI): correcting statements by clarifying on recall
-
-
-
-
-
-
-
Tevogen Bio (TVGN) Confirms Ongoing Efficacy of TVGN 489, Its Investigational Allogeneic Off-the-Shelf Immunotherapy, Against Dominant FLiRT Strains of SARS-CoV-2
-
-
-
-
-
-
-
LivaNova plc (LIVN) RECOVER Clinical Study Evaluating VNS Therapy for Treatment-Resistant Depression in Unipolar Patients Did Not Meet Primary Endpoint
-
-
-
-
-
-
-
Replimune (REPL) Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed Melanoma
-
67,359 total articles have been posted to this category.
Sign-up to StreetInsider.com Premium
to see all today's market moving FDA reports.
